CA2220038A1 - Device for the delivery of high dose pharmaceutical, neutraceutical, agricultural, biological, and chemical substances - Google Patents
Device for the delivery of high dose pharmaceutical, neutraceutical, agricultural, biological, and chemical substances Download PDFInfo
- Publication number
- CA2220038A1 CA2220038A1 CA 2220038 CA2220038A CA2220038A1 CA 2220038 A1 CA2220038 A1 CA 2220038A1 CA 2220038 CA2220038 CA 2220038 CA 2220038 A CA2220038 A CA 2220038A CA 2220038 A1 CA2220038 A1 CA 2220038A1
- Authority
- CA
- Canada
- Prior art keywords
- delivery device
- ethylcellulose
- tablets
- water soluble
- dialyzing membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/34—Shaped forms, e.g. sheets, not provided for in any other sub-group of this main group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Abstract
Compositions containing a pharmaceutical, neutraceutical, agricultural, biological, or chemical substance(s), and optionally together with pharmaceutical excipients such as fillers, diluents, lubricants, glidants, wetting agents, acidifiers, alkalinizers, buffering agents, disintegrants, pigments as the core material, one or more layers of dialyzing membrane comprising a non water soluble hydrophobic cellulose ether such as ethylcellulose and a nonionic water soluble hydrophilic poly(ethylene oxide) polymers of molecular weight greater than twenty five thousand which are swellable, gel forming and permeable at acid, neutral and alkaline pH, optionally containing pharmaceutical excipients such as plasticizers, pigments, lubricants, glidants the said dialyzing membrane being applied at a micro or macro level or both levels and a process for the compounding thereof.
Description
FIELD OF THE INVENTION
The present invention is related to novel compositions containing a pharmaceutical, neutraceutical, agricultural, biological, or chemical substance(s), and optionally together with pharmaceutical excipients such as fillers, diluents, lubricants, glidants, wetting agents, acidifiers, alkalinizers, buffering agents, disintegrants, pigments as the core material, one or more layers of dialyzing membrane comprising a non water soluble hydrophobic cellulose ether such as ethylcellulose and a nonionic water soluble hydrophilic polyethylene oxide) polymers of molecular weight greater than twenty five thousand which are swellable, gel forming and permeable at acid, neutral and alkaline pH, optionally containing pharmaceutical excipients such as plasticizers, pigments, lubricants, glidants the said dialyzing membrane being applied at a micro or macro level or both and a process for the compounding thereof. This device is capable of controlled, pulsitile, sustained, delayed, and site specific release or delivery of pharmaceutical, neutraceutical, agricultural, biological, or chemical substance(s). The device is particularly useful for the delivery of high dose water-soluble substances.
BACKGROUND TO THE INVENTION
High dose water-soluble substances are difficult or impossible to deliver in a controlled, pulsitile, sustained, delayed release fashion to the gastrointestinal tract.
This is because of compositional and manufacturing constraints that a high dose and high solubility present to people skilled in the act when applying current drug delivery technologies.
Substances such as Acyclovir, Niacin, Metformin and most neutraceuticals require a high dose to elicit their therapeutic activities. Using current delivery technology platforms for these types of substances will necessitate the presentation of a large oral dosage form, which may be difficult to swallow thus Inventors: Dr. Amina Odidi & Dr Isa Odidi Date: 1 September 1995 presenting a compliance problem. If on the contrary a smaller oral dosage form is desired, control or modification of the release properties of such a device is ineffective or at the very best i11 defined because there is simply no room left in the delivery device for the release modulating component to be incorporated after having accounted for the therapeutically active substances.
In order to get around this problem, a unique blend and composition of smart polymers comprising a water soluble, hydrophilic polymer and a water insoluble hydrophobic polymer is applied to the substances) on a micro level by granulation and/or at a macro level by coating tablets or pellets of the said substance(s). The special choice of these smart polymers and their composition allow for efficient controlled release of the substances) with minimal and optimum use of release modulating polymers in a compliant friendly dosage form.
SUMMARY OF THE INVENTION
This invention relates to a controlled release device for the controlled, pulsitile, sustained, delayed, and site specific release or delivery of high dose water soluble or insoluble pharmaceutical, neutraceutical, agricultural, biological, or chemical substance(s). This new preparation demonstrates excellent controlled release properties in acid, neutral and alkaline pH.
The new device has a good stability during long term storage. Thus according to the present invention there is provided a composition for the controlled, pulsitile, sustained, delayed, and site specific release or delivery of high dose water soluble or insoluble pharmaceutical, neutraceutical, agricultural, biological, or chemical substances) consisting of these substances) and optionally together with pharmaceutical excipients such as fillers, diluents, lubricants, glidants, wetting agents, acidifiers, alkalinizers, buffering agents, disintegrants, pigments as the core material, one or more layers of dialyzing membrane comprising a non water soluble hydrophobic cellulose ether Inventors: Dr. Amina Odidi & Dr Isa Odidi 4 Datc: 1 September l995 such as ethylcellulose and a nonionic water soluble hydrophilic polyethylene oxide) polymers of molecular weight greater than twenty five thousand which are swellable, gel forming and permeable at acid, neutral and alkaline pH, optionally containing pharmaceutical excipients such as plasticizers, pigments, lubricants, glidants the said dialyzing membrane being applied at a micro or macro level or both and a process for the compounding thereof.
DETAILED DESCRIPTION OF THE PREFERED EMBODIMENTS OF THE INVENTION
The water soluble or insoluble pharmaceutical, neutraceutical, agricultural, biological, or chemical substance is optionally mixed with inert pharmaceutical excipients such as diluents (lactose, starch, and microcrystalline cellulose), lubricants, glidants, wetting agents, acidifiers, alkalinizers, buffering agents, disintegrants, anti oxidants, preservatives, and pigments fillers) in a planetary mixer, fluidized bed granulator, V-blender or high shear mixer. To this homogeneous blend is added a unique blend of an alcoholic solution of non water soluble hydrophobic cellulose ether such as ethylcellulose and a nonionic water soluble hydrophilic polyethylene oxide) (PEO) polymers) of molecular weight greater than twenty five thousand. This is via a wet granulation process in a planetary mixer, fluidized bed granulator, or high shear mixer.
This constitute application of the ethylcellulose/PEO to the substances on a micro level.
The wet granules can be extruded and pelletized. Alternatively, the wet granules can be dried and pressed into tablets using conventional pharmaceutical processes.
These pellets/tablets or pellets/tablets made from granules of the substances granulated without ethylcellulose/PEO can be used as cores or placed in gelatin capsules and used as cores on which a ethylcellulose/PEO
layers) are applied. The ethylcellulose/PEO layers) is applied using either aqueous or solvent-Inventors: Dr. Amina Odidi & Dr Isa Odidi Date: 1 September l995 based pan, rotor processor and/or fluidized bed coating techniques. This constitute application of ethylcellulose/PEO on a macro level.
The ethylcellulose/PEO layer(s), optionally contains one or more pharmaceutical excipients such as plasticizers, lubricants and pigments. The thickness of the ethylcellulose/PEO
layers) is not less than 0.001 mg/cm2.
Finally, the process for the preparation of the compositions enumerated above forms another aspect of the embodiments of this invention. In a preferred embodiment, the substances) is intimately mixed with the chosen pharmaceutical fillers) using a, high shear granulator. The resulting homogeneous blend is wet granulated with an alcoholic solution of ethylcellulose/PEO.
The wet granules are dried in a tray dryer to a loss on drying (LOD) index of less than 5%, after which they are blended with a lubricants) and formed into pellets or tablets using conventional pharmaceutical techniques. After forming the pellets or tablets are further coated with ethylcellulose/PEO as previously described.
The finished product may be presented as tablets or pellets or both in a hard gelatin capsule. It is preferable that the tablets or hard gelatin capsules are stored together with a desiccant in order to maintain low moisture content during long term storage.
EXAMPLES
EXAMPLE 1 Niacin controlled release tablets Here is presented the application of a dialyzing membrane of ethylcellulose/PEO on a micro and macro level to modulate the release of niacin.
Inventors: Dr. Amina Odidi & Dr Isa Odidi 6 Date: 1 September 1995 I. Composition of Niacin tablets Niacin 1000.0 mg Ethylcellulose 50.0 mg Polyethylene oxide 15.0 mg Talc 4.0 mg Magnesium Stearate 4.0 mg Granulate, niacin with an alcoholic solution of ethylcellulose/PEO in a high shear mixer. Dry the wet granules in a tray dryer to an LOD of 1%. Mill the dried granules in a cone mill and then blended with talc, magnesium stearate in a V-blender and pressed into tablets.
II. Composition of Niacin coated tablets tablets from I l073.0 mg Ethylcellulose 50.0 mg Polyethylene oxide 15.0 mg Finely disperse ethylcellulose and polyethylene oxide in ethanol using a propeller mixer. Apply the ethylcellulose/PEO alcoholic solution unto the tablets in a perforated side vented coating pan.
.- Temperature and relative humidity of the manufacturing area should be no greater than 35~C and 50%.
EXAMPLE 2. Metformin controlled release pellets/tablets Here is presented the application of a dialyzing membrane of ethylcellulose/PEO on a micro level to modulate the release of Metformin.
I. Composition of Metformin pellets/tablets Metformin 250.0 mg Ethylcellulose 25.0 mg Polyethylene oxide 7.5 mg Talc 1.0 mg Magnesium Stearate 1.0 mg Granulate, Metformin with an alcoholic solution of ethylcellulose/PEO in a Hobart mixer. Dry the wet granules in a tray dryer to an LOD of 1%. Mill the dried granules in a cone mill and then blended with talc, magnesium stearate in a V-blender and pressed into pellets/tablets.
Alcoholic solution of ethylcellulose/PEO is prepared by finely dispersing ethylcellulose/PEO in ethanol using a propeller mixer Inventors: Dr. Amina Odidi & Dr Isa Odidi 7 Date: 1 September 1995 One or more of the enteric coated pellets/tablets are filled into hard gelatin capsules.
Temperature and relative humidity of the manufacturing area should be no greater than 35~C and 50%.
EXAMPLE 3. Acyclovir controlled release tablets Here is presented the application of a dialyzing membrane of ethylcellulose/PEO on a macro level to modulate the release of Acyclovir I. Composition of Acyclovir tablets Acyclovir 1000.0 mg Ethylcellulose l00.0 mg Polyethylene oxide 20.0 mg Talc 4.0 mg Magnesium Stearate 4.0 mg Granulate Acyclovir using an alcoholic solution in a high shear mixer. Dry the wet granules in a tray dryer until an LOD of less than 5% is achieved. Mill the granules and blend with talc and magnesium stearate in a V-blender. Compress the homogeneous blend into tablets. Prepare an alcoholic solution of ethylcellulose/PEO by finely dispersing ethylcellulose/PEO in ethanol using a propeller mixer. Coat the Acyclovir tablets with the alcoholic solution of ethylcellulose/PEO.
Temperature and relative humidity of the manufacturing area should be no greater than 35~C and 50%.
Inventors: Dr. Amina Odidi & Dr Isa Odidi 8 Date: 1 September l995
The present invention is related to novel compositions containing a pharmaceutical, neutraceutical, agricultural, biological, or chemical substance(s), and optionally together with pharmaceutical excipients such as fillers, diluents, lubricants, glidants, wetting agents, acidifiers, alkalinizers, buffering agents, disintegrants, pigments as the core material, one or more layers of dialyzing membrane comprising a non water soluble hydrophobic cellulose ether such as ethylcellulose and a nonionic water soluble hydrophilic polyethylene oxide) polymers of molecular weight greater than twenty five thousand which are swellable, gel forming and permeable at acid, neutral and alkaline pH, optionally containing pharmaceutical excipients such as plasticizers, pigments, lubricants, glidants the said dialyzing membrane being applied at a micro or macro level or both and a process for the compounding thereof. This device is capable of controlled, pulsitile, sustained, delayed, and site specific release or delivery of pharmaceutical, neutraceutical, agricultural, biological, or chemical substance(s). The device is particularly useful for the delivery of high dose water-soluble substances.
BACKGROUND TO THE INVENTION
High dose water-soluble substances are difficult or impossible to deliver in a controlled, pulsitile, sustained, delayed release fashion to the gastrointestinal tract.
This is because of compositional and manufacturing constraints that a high dose and high solubility present to people skilled in the act when applying current drug delivery technologies.
Substances such as Acyclovir, Niacin, Metformin and most neutraceuticals require a high dose to elicit their therapeutic activities. Using current delivery technology platforms for these types of substances will necessitate the presentation of a large oral dosage form, which may be difficult to swallow thus Inventors: Dr. Amina Odidi & Dr Isa Odidi Date: 1 September 1995 presenting a compliance problem. If on the contrary a smaller oral dosage form is desired, control or modification of the release properties of such a device is ineffective or at the very best i11 defined because there is simply no room left in the delivery device for the release modulating component to be incorporated after having accounted for the therapeutically active substances.
In order to get around this problem, a unique blend and composition of smart polymers comprising a water soluble, hydrophilic polymer and a water insoluble hydrophobic polymer is applied to the substances) on a micro level by granulation and/or at a macro level by coating tablets or pellets of the said substance(s). The special choice of these smart polymers and their composition allow for efficient controlled release of the substances) with minimal and optimum use of release modulating polymers in a compliant friendly dosage form.
SUMMARY OF THE INVENTION
This invention relates to a controlled release device for the controlled, pulsitile, sustained, delayed, and site specific release or delivery of high dose water soluble or insoluble pharmaceutical, neutraceutical, agricultural, biological, or chemical substance(s). This new preparation demonstrates excellent controlled release properties in acid, neutral and alkaline pH.
The new device has a good stability during long term storage. Thus according to the present invention there is provided a composition for the controlled, pulsitile, sustained, delayed, and site specific release or delivery of high dose water soluble or insoluble pharmaceutical, neutraceutical, agricultural, biological, or chemical substances) consisting of these substances) and optionally together with pharmaceutical excipients such as fillers, diluents, lubricants, glidants, wetting agents, acidifiers, alkalinizers, buffering agents, disintegrants, pigments as the core material, one or more layers of dialyzing membrane comprising a non water soluble hydrophobic cellulose ether Inventors: Dr. Amina Odidi & Dr Isa Odidi 4 Datc: 1 September l995 such as ethylcellulose and a nonionic water soluble hydrophilic polyethylene oxide) polymers of molecular weight greater than twenty five thousand which are swellable, gel forming and permeable at acid, neutral and alkaline pH, optionally containing pharmaceutical excipients such as plasticizers, pigments, lubricants, glidants the said dialyzing membrane being applied at a micro or macro level or both and a process for the compounding thereof.
DETAILED DESCRIPTION OF THE PREFERED EMBODIMENTS OF THE INVENTION
The water soluble or insoluble pharmaceutical, neutraceutical, agricultural, biological, or chemical substance is optionally mixed with inert pharmaceutical excipients such as diluents (lactose, starch, and microcrystalline cellulose), lubricants, glidants, wetting agents, acidifiers, alkalinizers, buffering agents, disintegrants, anti oxidants, preservatives, and pigments fillers) in a planetary mixer, fluidized bed granulator, V-blender or high shear mixer. To this homogeneous blend is added a unique blend of an alcoholic solution of non water soluble hydrophobic cellulose ether such as ethylcellulose and a nonionic water soluble hydrophilic polyethylene oxide) (PEO) polymers) of molecular weight greater than twenty five thousand. This is via a wet granulation process in a planetary mixer, fluidized bed granulator, or high shear mixer.
This constitute application of the ethylcellulose/PEO to the substances on a micro level.
The wet granules can be extruded and pelletized. Alternatively, the wet granules can be dried and pressed into tablets using conventional pharmaceutical processes.
These pellets/tablets or pellets/tablets made from granules of the substances granulated without ethylcellulose/PEO can be used as cores or placed in gelatin capsules and used as cores on which a ethylcellulose/PEO
layers) are applied. The ethylcellulose/PEO layers) is applied using either aqueous or solvent-Inventors: Dr. Amina Odidi & Dr Isa Odidi Date: 1 September l995 based pan, rotor processor and/or fluidized bed coating techniques. This constitute application of ethylcellulose/PEO on a macro level.
The ethylcellulose/PEO layer(s), optionally contains one or more pharmaceutical excipients such as plasticizers, lubricants and pigments. The thickness of the ethylcellulose/PEO
layers) is not less than 0.001 mg/cm2.
Finally, the process for the preparation of the compositions enumerated above forms another aspect of the embodiments of this invention. In a preferred embodiment, the substances) is intimately mixed with the chosen pharmaceutical fillers) using a, high shear granulator. The resulting homogeneous blend is wet granulated with an alcoholic solution of ethylcellulose/PEO.
The wet granules are dried in a tray dryer to a loss on drying (LOD) index of less than 5%, after which they are blended with a lubricants) and formed into pellets or tablets using conventional pharmaceutical techniques. After forming the pellets or tablets are further coated with ethylcellulose/PEO as previously described.
The finished product may be presented as tablets or pellets or both in a hard gelatin capsule. It is preferable that the tablets or hard gelatin capsules are stored together with a desiccant in order to maintain low moisture content during long term storage.
EXAMPLES
EXAMPLE 1 Niacin controlled release tablets Here is presented the application of a dialyzing membrane of ethylcellulose/PEO on a micro and macro level to modulate the release of niacin.
Inventors: Dr. Amina Odidi & Dr Isa Odidi 6 Date: 1 September 1995 I. Composition of Niacin tablets Niacin 1000.0 mg Ethylcellulose 50.0 mg Polyethylene oxide 15.0 mg Talc 4.0 mg Magnesium Stearate 4.0 mg Granulate, niacin with an alcoholic solution of ethylcellulose/PEO in a high shear mixer. Dry the wet granules in a tray dryer to an LOD of 1%. Mill the dried granules in a cone mill and then blended with talc, magnesium stearate in a V-blender and pressed into tablets.
II. Composition of Niacin coated tablets tablets from I l073.0 mg Ethylcellulose 50.0 mg Polyethylene oxide 15.0 mg Finely disperse ethylcellulose and polyethylene oxide in ethanol using a propeller mixer. Apply the ethylcellulose/PEO alcoholic solution unto the tablets in a perforated side vented coating pan.
.- Temperature and relative humidity of the manufacturing area should be no greater than 35~C and 50%.
EXAMPLE 2. Metformin controlled release pellets/tablets Here is presented the application of a dialyzing membrane of ethylcellulose/PEO on a micro level to modulate the release of Metformin.
I. Composition of Metformin pellets/tablets Metformin 250.0 mg Ethylcellulose 25.0 mg Polyethylene oxide 7.5 mg Talc 1.0 mg Magnesium Stearate 1.0 mg Granulate, Metformin with an alcoholic solution of ethylcellulose/PEO in a Hobart mixer. Dry the wet granules in a tray dryer to an LOD of 1%. Mill the dried granules in a cone mill and then blended with talc, magnesium stearate in a V-blender and pressed into pellets/tablets.
Alcoholic solution of ethylcellulose/PEO is prepared by finely dispersing ethylcellulose/PEO in ethanol using a propeller mixer Inventors: Dr. Amina Odidi & Dr Isa Odidi 7 Date: 1 September 1995 One or more of the enteric coated pellets/tablets are filled into hard gelatin capsules.
Temperature and relative humidity of the manufacturing area should be no greater than 35~C and 50%.
EXAMPLE 3. Acyclovir controlled release tablets Here is presented the application of a dialyzing membrane of ethylcellulose/PEO on a macro level to modulate the release of Acyclovir I. Composition of Acyclovir tablets Acyclovir 1000.0 mg Ethylcellulose l00.0 mg Polyethylene oxide 20.0 mg Talc 4.0 mg Magnesium Stearate 4.0 mg Granulate Acyclovir using an alcoholic solution in a high shear mixer. Dry the wet granules in a tray dryer until an LOD of less than 5% is achieved. Mill the granules and blend with talc and magnesium stearate in a V-blender. Compress the homogeneous blend into tablets. Prepare an alcoholic solution of ethylcellulose/PEO by finely dispersing ethylcellulose/PEO in ethanol using a propeller mixer. Coat the Acyclovir tablets with the alcoholic solution of ethylcellulose/PEO.
Temperature and relative humidity of the manufacturing area should be no greater than 35~C and 50%.
Inventors: Dr. Amina Odidi & Dr Isa Odidi 8 Date: 1 September l995
Claims (13)
1. A delivery device in which water soluble or insoluble low, medium and high dose pharmaceutical, neutraceutical, agricultural, biological, or chemical substance(s) optionally mixed with inert pharmaceutical excipients is coated with one or more layers of dialyzing membrane.
2. A delivery device in which the dialyzing membrane consists of non water soluble hydrophobic cellulose ether such as ethylcellulose and/or a nonionic water soluble hydrophilic polyethylene oxide) (PEO) polymer(s) of molecular weight greater than twenty five thousand and/or the active substance(s).
3. A delivery device according to claim 1 and 2 in which the dialyzing membrane is applied at a micro level via wet granulation
4. A delivery device according to claim 1 and 2 in which the dialyzing membrane is applied at a macro level via coating of pellets/tablets
5. A delivery device according to claim 1 and 2 in which the dialyzing membrane is first applied at a micro level via wet granulation and later at a macro level via coating of pellets/tablets made from the micro coated granules.
6. A delivery device according to claim 1 and 2 in which the pharmaceutical excipients are chosen from the group fillers, diluents, lubricants, glidants, wetting agents, acidifiers, alkalinizers, buffering agents, disintegrants, pigments.
7. A delivery device according to claim 1 and 2 in which the said dialyzing membrane contains pharmaceutical excipients such as plasticizers, pigments, lubricants, and glidants.
8. A delivery device according to claim 1 and 2 in which the pellets/tablets can be used as cores or placed in gelatin capsules and used as cores on which a ethylcellulose/PEO
layer(s) are applied.
layer(s) are applied.
9. A delivery device according to claim 1 and 2 in which the ethylcellulose/PEO layer(s) is applied using either aqueous or solvent based pan, rotor processor and/or fluidized bed coating techniques
10. A preparation according to claim 1 and 2, wherein the active substance(s) is niacin, Acyclovir, Metformin.
11. A preparation according to claim 1 and 2, wherein the finished product is presented as tablets or pellets or both in a hard gelatin capsule and stored together with a desiccant in order to maintain low moisture content during long term storage.
12. A preparation according to claim 1 and 2 which is capable of controlled, pulsitile, sustained, delayed, and site specific release of water soluble or insoluble low, medium or high dose pharmaceutical, neutraceutical, agricultural, biological, or chemical substance(s).
13. A delivery device according to claims 1 and 2 in which an asymptote is reached or 80% of the active substance(s) is released within 48 hours in acid, neutral or alkaline media using USP dissolution Apparatus <I>, <II>, <III> or <IV>.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2220038 CA2220038A1 (en) | 1998-01-05 | 1998-01-05 | Device for the delivery of high dose pharmaceutical, neutraceutical, agricultural, biological, and chemical substances |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2220038 CA2220038A1 (en) | 1998-01-05 | 1998-01-05 | Device for the delivery of high dose pharmaceutical, neutraceutical, agricultural, biological, and chemical substances |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2220038A1 true CA2220038A1 (en) | 1999-07-05 |
Family
ID=29275151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2220038 Abandoned CA2220038A1 (en) | 1998-01-05 | 1998-01-05 | Device for the delivery of high dose pharmaceutical, neutraceutical, agricultural, biological, and chemical substances |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2220038A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
| US7731989B2 (en) | 2001-10-25 | 2010-06-08 | Depomed, Inc. | Gastric retained gabapentin dosage form |
| US7736667B2 (en) * | 2000-02-04 | 2010-06-15 | Depomed, Inc. | Shell-and-core dosage form approaching zero-order drug release |
| US8580302B2 (en) | 2000-11-20 | 2013-11-12 | Warner Chilcott Company, Llc | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
| US8592481B2 (en) | 2005-12-29 | 2013-11-26 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
-
1998
- 1998-01-05 CA CA 2220038 patent/CA2220038A1/en not_active Abandoned
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8329215B2 (en) | 2000-02-04 | 2012-12-11 | Depomed, Inc. | Shell and core dosage form approaching zero-order drug release |
| US9597338B2 (en) | 2000-02-04 | 2017-03-21 | Depomed, Inc. | Shell-and-core dosage form approaching zero-order drug release |
| US7736667B2 (en) * | 2000-02-04 | 2010-06-15 | Depomed, Inc. | Shell-and-core dosage form approaching zero-order drug release |
| US8043630B2 (en) | 2000-02-04 | 2011-10-25 | Depomed, Inc. | Shell-and-core dosage form approaching zero-order drug release |
| US8945619B2 (en) | 2000-02-04 | 2015-02-03 | Depomed, Inc. | Shell-and-core dosage form approaching zero-order drug release |
| US9089492B2 (en) | 2000-11-20 | 2015-07-28 | Warner Chilcott Company, Llc | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
| US8580302B2 (en) | 2000-11-20 | 2013-11-12 | Warner Chilcott Company, Llc | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
| US8333991B2 (en) | 2001-10-25 | 2012-12-18 | Depomed, Inc. | Gastric retained gabapentin dosage form |
| US8529955B2 (en) | 2001-10-25 | 2013-09-10 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
| US8333992B2 (en) | 2001-10-25 | 2012-12-18 | Depomed, Inc. | Gastric retained gabapentin dosage form |
| US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
| US8409613B2 (en) | 2001-10-25 | 2013-04-02 | Depomed, Inc. | Gastric retained gabapentin dosage form |
| US8440232B2 (en) | 2001-10-25 | 2013-05-14 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
| US8475813B2 (en) | 2001-10-25 | 2013-07-02 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
| US8252332B2 (en) | 2001-10-25 | 2012-08-28 | Depomed Inc | Gastric retained gabapentin dosage form |
| US8580303B2 (en) | 2001-10-25 | 2013-11-12 | Depomed, Inc. | Gastric retained gabapentin dosage form |
| US8231905B2 (en) | 2001-10-25 | 2012-07-31 | Depomed, Inc. | Gastric retained gabapentin dosage form |
| US7731989B2 (en) | 2001-10-25 | 2010-06-08 | Depomed, Inc. | Gastric retained gabapentin dosage form |
| US8802157B2 (en) | 2001-10-25 | 2014-08-12 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage form |
| US8192756B2 (en) | 2001-10-25 | 2012-06-05 | Depomed, Inc. | Gastric retained gabapentin dosage form |
| US8119166B2 (en) | 2001-10-25 | 2012-02-21 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
| US8592481B2 (en) | 2005-12-29 | 2013-11-26 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6479075B1 (en) | Pharmaceutical formulations for acid labile substances | |
| US6893661B1 (en) | Controlled release formulations using intelligent polymers | |
| EP2555756B1 (en) | Controlled release pharmaceutical compositions of tapentadol | |
| CN1407884B (en) | Controlled release hydrocodone formulations | |
| RU2376983C2 (en) | Gastral retentive compositions and its production methods | |
| DK174992B1 (en) | Slow release pharmaceutical composition and use of certain additives therein to achieve slow release | |
| RU2375048C2 (en) | Pharmacological composition with swelling coating | |
| KR19990028693A (en) | Release Modification Formulations of Insoluble Drugs | |
| SK282854B6 (en) | Controlled-release dosage forms of azithromycin | |
| AU2002366029B2 (en) | Preparation compositions containing acid-unstable physiologically active compounds and process for producing the same | |
| US9387178B2 (en) | Modified release tranexamic acid formulation | |
| US20090148519A1 (en) | Pulsed-release preparation having improved disintegration properties in vivo | |
| EP1813275A1 (en) | Lansoprazole orally disintegrating tablets | |
| AU2004259226B2 (en) | Pharmaceutical compositions having a swellable coating | |
| US20010001658A1 (en) | Granule modulating hydrogel system | |
| WO2007075980A2 (en) | Lansoprazole orally disintegrating tablets | |
| US20030091634A1 (en) | Delayed release tablet of venlafaxin | |
| CA2220038A1 (en) | Device for the delivery of high dose pharmaceutical, neutraceutical, agricultural, biological, and chemical substances | |
| US20030059466A1 (en) | Delayed release tablet of venlafaxin | |
| US20050163846A1 (en) | Preparation composition containing acid-unstable physiologically active compound, and process for producing same | |
| MXPA05004648A (en) | Oral extended release tablets and methods of making and using the same. | |
| WO2005051348A2 (en) | Enteric-coated tablets of pantoprazole | |
| JPH0130A (en) | sustained release formulation | |
| US20040228918A1 (en) | Granule modulating hydrogel system | |
| WO2011086568A1 (en) | Controlled release composition for lamotrigine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |